20 episodes

OUR MISSION
To facilitate tangible improvements in the lives of people who have been affected by cancer(s), by providing them and their loved ones the necessary survival tools, education, support and advocacy so that they can become responsible for and take an active role in their own medical care and wellbeing.
OUR GOAL
Our goal is to teach all people affected by cancer, including those with multiple cancers and/or rare cancers, to become CANCER THRIVERS.

Cancer ABCs From Surviving To Thriving - How to Thrive with Cancer Joel Nowak Cancer ABCs

    • Health & Fitness
    • 4.8 • 6 Ratings

OUR MISSION
To facilitate tangible improvements in the lives of people who have been affected by cancer(s), by providing them and their loved ones the necessary survival tools, education, support and advocacy so that they can become responsible for and take an active role in their own medical care and wellbeing.
OUR GOAL
Our goal is to teach all people affected by cancer, including those with multiple cancers and/or rare cancers, to become CANCER THRIVERS.

    New Orleans Music Producer Shane Norris Diagnosed with Prostate Cancer During Covid Shares His Journey with HIFU Treatment

    New Orleans Music Producer Shane Norris Diagnosed with Prostate Cancer During Covid Shares His Journey with HIFU Treatment

    Joel Nowak and Shane Norris discuss his unusual Covid Pandemic Journey with a new prostate cancer diagnosis.  Shane, a well-respected music producer and gig worker, joined with other New Orleans artists to raise funds for out-of-work musicians.  As he began to create a fund raising vehicle he was diagnosed with prostate cancer.  

    Shane shares the experience he had navigating the Covid pandemic as he searched for the prostate cancer treatment that he felt best suited his needs.  With financial support raised from a GO-Fund-Me project as well as help and guidance from a number of resources, including medical professionals, family and friends, Shane decided to become the first man in Louisiana to treat his prostate cancer with high intensity focused ultrasound – or HIFU. 
    Despite Shane having to learn about prostate cancer and potential treatments and their possible side effects, in the middle of a pandemic, he and his colleagues managed to raise and distribute $400,000 to out-of-work New Orleans artists.   

    Some Important Additional Information:
     1-  High Intensity Focal Ultrasound (HIFU) currently has a CPT code, and is covered by Medicare, with a deductible. HIFU is also covered by some private insurance carriers for both initial treatment and as a salvage therapy.  Please check with your insurance carrier (Medicare and private carriers) to confirm your specific coverages.  With the CPT code urology practices can now submit claims to private insurers which are evaluated for reimbursement on a case by case basis. 
    2-  Shane's personal experience with side effects from his HIFU treatment does not guarantee that others having HIFU will have the same experience.  Following HIFU patients may be required to have a catheter inserted for 3 to 7 days.  The risk of having the more common side effects of urinary incontinence and sexual dysfunction seen in treating the entire gland are minimized due to HIFU's targeted nature of  tumor ablation. 
     
    Support the show (https://www.cancerabcs.org/new-page-2/)

    • 26 min
    Understanding the Importance of Radiopharmaceutical Scans and Why They Might Not Be Available for Us When We Need Them

    Understanding the Importance of Radiopharmaceutical Scans and Why They Might Not Be Available for Us When We Need Them

    Radiopharmaceutical scans (PETS) are a vital tool in our fight against cancer. 

    These special PET scans allow us to make earlier cancer diagnoses while a cancer is still contained in the original organ.   With an earlier diagnosis, treatments can still stop the cancer before it is able to move to other parts of the body, or become metastatic.  

    These special scans also are our best tools to evaluate whether our treatments are working, or if we have developed resistance to the treatments.  FDA approved treatments are limited, so we have  to take full advantage of them while they work.  Since most treatments will eventually stop working, we need to also have an immediate and accurate way to measure whether we are still benefiting from our treatments, or have developed resistance to them.

    Sadly, the future of these scans is in jeopardy.  The current insurance reimbursement schedule only supports the use of these scans for three years, after which reimbursement rates might not cover the costs, making these very important scans unavailable despite having been approved by the FDA.  Currently these scans could be looking  at a 3 year life, after which adequate reimbursement might disappear (as will the availability of the scan to patients). 

    Cancer ABCs is working to change the law so that reimbursement of these scans will keep them affordable and available as we need them.  Join us and help us preserve the availability of these scans.  To learn more about this issue,  and to lend your support, reach out to us at info@CancerABCs.org

    Cancer ABCs is proud to have and to thank our wonderful podcast sponsors:
    Foundation MedicineMyovant Dendreon


    Support the show (https://www.cancerabcs.org/new-page-2/)

    • 12 min
    Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment

    Survival with Provenge - Real World Data Along with A Peek Into the Future of Treatment

    Joel T Nowak from Cancer ABCs discusses with Dr. Rana McKay, Associate Professor of Medicine at the Moores Cancer Center at the University of California in San Diego,  her recently published article that analysizes real world data that demonstrates that Provenge (sipuleucel-T), an immune therapy for castrate  resistant metastatic prostate cancer (mCRPC), can reduce the risk of death over and above the newer  hormone treatments that have been FDA approved . 

    Dr, McKay evaluated a large medicare data base and determined that despite the addition of the many second generation hormone treatments like Zytiga and Xtandi,  Provenge continues to lower the risk of death for men with mCRPC.  

    Dr. Mckay also shared a peek into the future of additional immune therapies for prostate cancer as well as sharing information about the newly FDA approved part inhibitors.  
    Support the show (https://www.cancerabcs.org/new-page-2/)

    • 25 min
    Is ADT Hormone Therapy Necessary When You Take Abiraterone Acetate aka Zytiga?

    Is ADT Hormone Therapy Necessary When You Take Abiraterone Acetate aka Zytiga?

    One of the most common question men with prostate cancer ask us at Cancer ABCs is if they can stop their hormone therapy (ADT) when they go on a second generation hormone treatment like abiraterone (Zytiga).

    A recent analysis of the SPARE Trial points us in the direction that it might be possible to halt ADT when you are taking Zytiga.  SPARE was a small trial which needs to be replicated by a larger trial before we can gain confidence in this conclusion. 

    SPARE did not evaluate what, if any change. stopping ADT  when you are on Zytiga might have on survival, economic costs and the quality of life.  
    Support the show (https://www.cancerabcs.org/new-page-2/)

    • 6 min
    Dealing with Salvage Radiation Side Effects for Prostate Cancer- One Mans Extraordinary Journey

    Dealing with Salvage Radiation Side Effects for Prostate Cancer- One Mans Extraordinary Journey

    Men who have a local prostate cancer recurrence, or their PSA starts increasing, after having prostate cancer surgery (a radical prostatectomy), the treatment of choice is considered salvage radiotherapy (SRT). In the post prostatectomy setting, SRT may impose significant risks and complications.
    Potential complications or side effects can include incontinence, bladder neck contracture, bladder and bowel symptoms, needing secondary procedures, as well as secondary malignancies. Radiation should never be considered non-invasive, but it can halt the progression of the cancer. Therefore, reserving radiotherapy for those who will most benefit is of great concern.
    In this podcast Joel Nowak speaks with Mr. John Harrison who had salvage radiation and has experienced many of these side effects.  On two occasions John has used Hyperbaric Oxygen Treatment which he describes as well as having a colostomy to allow his colon to  rest and hopefully heal.  
    In addition to having deal with radiation toxicities, he still has to be treated for his progressing prostate cancer.  John has just completed a Phase II Clinical Trial as well as using Lupron, aka Hormone Therapy (ADT). 
    To date, John has had limited relief from his symptoms, but his cancer is under control. 
    John shares his journey and experiences treating his side effects from both the surgery and the salvage radiation. Despite all of his symptoms he maintains a positive attitude and reminds us that his experiences are his and do not reflect what others might experience.

    John considers himself an outlier. As an outlier he offers some sage advice for all of us who are being treated for prostate cancer.  
    Support the show (https://www.cancerabcs.org/new-page-2/)

    • 27 min
    Protect Yourself - Know the Limits of the Genetic Privacy Laws

    Protect Yourself - Know the Limits of the Genetic Privacy Laws

    Genetic testing plays a major role in identifying an individual's risk for developing cancer as well as the management of many different cancers, including prostate cancer.  It's important that we patients know the limits of a key federal privacy law that is supposed to protect us when we do have a genetic test.

    In June, 2020, there was a  new set of recommendations on the use of genetic testing published by the International Philadelphia Prostate Cancer Consensus Conference that strongly endorses the testing of all men with metastatic prostate cancer to aid with treatment decisions and to assess eligibility for clinical trials.
     It is important that we understand that there are significant limits to the Genetic Information Nondiscrimination Act (GINA) of 2008, which was written to protect against discrimination in employment and medical insurance for people with known genetic risk factors for diseases, including cancer.  
     
    Support the show (https://www.cancerabcs.org/new-page-2/)

    • 5 min

Customer Reviews

4.8 out of 5
6 Ratings

6 Ratings

ketotruck ,

One of the better cancer websites just got a great podcast

This is one of the better websites. I have advanced prostate cancer and I am learning so much about thriving with this disease. The podcast is very informative.

Charlie and friend ,

Terrific Podcast

Cancer is a difficult topic to present well to a wide audience for many reasons. This podcast makes complicated material understandable and useful to a variety of listeners without in any way losing any of the important details. Looking forward to more of these, particularly interviews of the people truly in the trenches. Thanks, Joel T. Nowak and Cancer ABCs.

bsnoa ,

Cancer abcs

Very informative podcast. I learned an enormous amount. Thanks.

Top Podcasts In Health & Fitness